Projects
This section presents pharmaceutical projects that are announced from time-to-time around the world.
Cincinnati Children's Hospital Invests US$42 million to Open Research Pavilion in Avondale, USA
Cincinnati Children invests US$42 million to open new research pavilion The site will become new home for several critical facilities, including the vaccine research center, a biobank, and a freezer archive
Kindeva to Invest US$42 million(£33m) to Enhance Inhaler Manufacturing in UK
Kindeva reveives an investment support of US$42 million33m from the UK government to enhanc inhaler manufacturing and sustainability
Oxford Properties Group Invests US$91 million for GMP Facility in USA
Oxford Properties Group sells stateoftheart GMP facility in Marlborough,USA for US$91 million to Moderna
Upperton Pharma Solutions Constructs US$19 million (£15m) GMP Manufacturing Facility in Nottingham, UK
Upperton Pharma Solutions has completed the building of its new development and GMP manufacturing facility with an investment of US$19 million 15m
Yposkesi Opens New US$65. 3 million (€60 million) Site to Manufacture Cell and Gene Therapies in France
Yposkesi plans to open new bioproduction site with an investment of US$65 3 million 60 million for manufacturing cell and gene therapies
Berkshire Sterile Plans to Expand Lyophilisation Capacity in USA
Berkshire Sterile Manufacturing plans to add an additional lyophiliser to their infrastructure in USA
Vaxxas Unveils Manufacturing Facility in Queensland, Australia
Vaxxas unveils worldclass facility for needlefree vaccine patch production and commercial products in Queensland, Australia
Biovian Unveils Plan for US$54 million (€50 million) Manufacturing Facility Investment in Turku, Finland
Biovian has unveiled plans to make an investment of US$54 million 50 million in expanding its manufacturing facility in Turku, Finland
Merck Invests US$27 million (€23 million) to Expand Cell Culture Media Production in USA
Merck invests US$27 million 23 million to expand Cell Culture Media Manufacturing facility in Kansas, USA
Sandoz Invests US$90 million to Open Biosimilar Technical Development Centre in Slovenia, Europe
The new stateoftheart endtoend drug product development centre represents a significant investment in biopharma technical development capabilities
